Literature DB >> 15056283

Phosphatidylinositol-3 kinase is distinctively required for mu-, but not kappa-opioid receptor-induced activation of c-Jun N-terminal kinase.

Angel Y F Kam1, Anthony S L Chan, Yung H Wong.   

Abstract

Opioid receptors are the therapeutic targets of narcotic analgesics. All three types of opioid receptors (mu, delta and kappa) are prototypical G(i)-coupled receptors with common signaling characteristics in their regulation of intracellular events. Nevertheless, numerous signaling processes are differentially regulated by the three receptors. We have recently demonstrated that stimulation of delta-opioid receptor can up-regulate the activity of the c-Jun N-terminal kinase (JNK) in a pertussis toxin-sensitive manner (Kam et al. 2003; J. Neurochem. 84, 503-513). The present study revealed that the mu-opioid receptor could stimulate JNK in both SH-SY5Y cells and transfected COS-7 cells. The mechanism by which the mu-opioid receptor stimulated JNK was delineated with the use of specific inhibitors and dominant-negative mutants of signaling intermediates. Activation of JNK by the mu-opioid receptor was mediated through G beta gamma, Src kinase, son-of-sevenless (Sos), Rac and Cdc42. Interestingly, unlike the delta-opioid receptors, the mu-opioid receptor required phosphatidylinositol-3 kinase (PI3K) to activate JNK. The mu-opioid receptor-induced JNK activation was effectively inhibited by wortmannin or the coexpression of a dominant negative mutant of PI3K gamma. Like the delta-opioid receptor, activation of JNK by the kappa-opioid receptor occurred in a PI3K-independent manner. These studies revealed that the mu-opioid receptor utilize a distinct mechanism to regulate JNK.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056283     DOI: 10.1111/j.1471-4159.2004.02338.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Authors:  Erica J Melief; Mayumi Miyatake; Michael R Bruchas; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-03       Impact factor: 11.205

Review 2.  Morphine as a treatment of cancer-induced pain-is it safe? A review of in vivo studies and mechanisms.

Authors:  David Brinkman; Jiang H Wang; Henry P Redmond
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-09-20       Impact factor: 3.000

3.  Novel biomarkers to assess in utero effects of maternal opioid use: First steps toward understanding short- and long-term neurodevelopmental sequelae.

Authors:  Laura Goetzl; Tara Thompson-Felix; Nune Darbinian; Nana Merabova; Salim Merali; Carmen Merali; Kathryne Sanserino; Tamara Tatevosian; Bruno Fant; Mathieu E Wimmer
Journal:  Genes Brain Behav       Date:  2019-06-11       Impact factor: 3.449

4.  Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.

Authors:  Raehannah J Jamshidi; Laura C Sullivan; Blaine A Jacobs; Teresa A Chavera; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-07       Impact factor: 4.030

5.  Reactive oxygen species (ROS) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 mitogen-activated protein kinase (MAPK) activation.

Authors:  Selena S Schattauer; Andrea Bedini; Floyd Summers; Aiden Reilly-Treat; Mackenzie M Andrews; Benjamin B Land; Charles Chavkin
Journal:  J Biol Chem       Date:  2019-10-01       Impact factor: 5.157

Review 6.  Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Authors:  Michael R Bruchas; Charles Chavkin
Journal:  Psychopharmacology (Berl)       Date:  2010-04-17       Impact factor: 4.530

Review 7.  Molecular mechanisms of opioid receptor-dependent signaling and behavior.

Authors:  Ream Al-Hasani; Michael R Bruchas
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

8.  Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells.

Authors:  Yadav Wagley; Cheol Kyu Hwang; Hong-Yiou Lin; Angel F Y Kam; Ping-Yee Law; Horace H Loh; Li-Na Wei
Journal:  Biochim Biophys Acta       Date:  2013-02-26

9.  Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms.

Authors:  Jamie Rose Kuhar; Andrea Bedini; Erica J Melief; Yen-Chen Chiu; Heather N Striegel; Charles Chavkin
Journal:  Cell Signal       Date:  2015-06-05       Impact factor: 4.315

10.  Mutations on the Switch III region and the alpha3 helix of Galpha16 differentially affect receptor coupling and regulation of downstream effectors.

Authors:  May Ym Yu; Maurice Kc Ho; Andrew Mf Liu; Yung H Wong
Journal:  J Mol Signal       Date:  2008-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.